BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 15446810)

  • 1. 4D-fingerprints, universal QSAR and QSPR descriptors.
    Senese CL; Duca J; Pan D; Hopfinger AJ; Tseng YJ
    J Chem Inf Comput Sci; 2004; 44(5):1526-39. PubMed ID: 15446810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative structure-based design: formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase.
    Pan D; Tseng Y; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(5):1591-607. PubMed ID: 14502494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease.
    Senese CL; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(4):1297-307. PubMed ID: 12870923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
    Santos-Filho OA; Hopfinger AJ
    J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4D-QSAR analysis of a series of antifungal p450 inhibitors and 3D-pharmacophore comparisons as a function of alignment.
    Liu J; Pan D; Tseng Y; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(6):2170-9. PubMed ID: 14632469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR modeling using chirality descriptors derived from molecular topology.
    Golbraikh A; Tropsha A
    J Chem Inf Comput Sci; 2003; 43(1):144-54. PubMed ID: 12546547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LQTA-QSAR: a new 4D-QSAR methodology.
    Martins JP; Barbosa EG; Pasqualoto KF; Ferreira MM
    J Chem Inf Model; 2009 Jun; 49(6):1428-36. PubMed ID: 19422246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
    Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
    J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating chemical diversity in QSAR analysis: modeling diverse HIV-1 integrase inhibitors using 4D fingerprints.
    Iyer M; Hopfinger AJ
    J Chem Inf Model; 2007; 47(5):1945-60. PubMed ID: 17661457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-pharmacophores of flavonoid binding at the benzodiazepine GABA(A) receptor site using 4D-QSAR analysis.
    Hong X; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(1):324-36. PubMed ID: 12546568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F.
    Wang XS; Tang H; Golbraikh A; Tropsha A
    J Chem Inf Model; 2008 May; 48(5):997-1013. PubMed ID: 18470978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple clustering technique to improve QSAR model selection and predictivity: application to a receptor independent 4D-QSAR analysis of cyclic urea derived inhibitors of HIV-1 protease.
    Senese CL; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(6):2180-93. PubMed ID: 14632470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mold(2), molecular descriptors from 2D structures for chemoinformatics and toxicoinformatics.
    Hong H; Xie Q; Ge W; Qian F; Fang H; Shi L; Su Z; Perkins R; Tong W
    J Chem Inf Model; 2008 Jul; 48(7):1337-44. PubMed ID: 18564836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
    Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
    Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
    Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
    J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The signature molecular descriptor. 1. Using extended valence sequences in QSAR and QSPR studies.
    Faulon JL; Visco DP; Pophale RS
    J Chem Inf Comput Sci; 2003; 43(3):707-20. PubMed ID: 12767129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial QSAR modeling of P-glycoprotein substrates.
    de Cerqueira Lima P; Golbraikh A; Oloff S; Xiao Y; Tropsha A
    J Chem Inf Model; 2006; 46(3):1245-54. PubMed ID: 16711744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of QSAR sets with a self-organizing map.
    Guha R; Serra JR; Jurs PC
    J Mol Graph Model; 2004 Sep; 23(1):1-14. PubMed ID: 15331049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
    Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
    J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR analyses of skin penetration enhancers.
    Iyer M; Zheng T; Hopfinger AJ; Tseng YJ
    J Chem Inf Model; 2007; 47(3):1130-49. PubMed ID: 17472334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.